Regencell Bioscience Holdings shares fall 1.67% in premarket due to technical correction and investor concerns over valuation.

Regencell Bioscience Holdings Limited plunged 1.67% in premarket trading, following a 10.41% single-day drop on July 9, 2025, as investors reacted to a technical correction after a significant rally. The company's lack of revenue and weak fundamentals, as disclosed in its 2024 annual report, also contributed to the sell-off, with technical analysis indicating a neutral to bearish short-term trend.